827331-49-7

Basic information

• Product Name: 3-(4-hydroxyphenyl)-N-methoxy-N-methylpropanamide
• Synonyms: 3-(4-hydroxyphenyl)-N-methoxy-N-methylpropanamide
• CAS NO: 827331-49-7
• Molecular Weight: 209.245
• Mol File: 827331-49-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(4-hydroxyphenyl)-N-methoxy-N-methylpropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-hydroxyphenyl)-N-methoxy-N-methylpropanamide(827331-49-7)
• EPA Substance Registry System: 3-(4-hydroxyphenyl)-N-methoxy-N-methylpropanamide(827331-49-7)

Safety Data

• Hazardous Substances Data: 827331-49-7(Hazardous Substances Data)

Upstream product

• 501-97-3 4-hydroxyphenylpropionic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 135639-22-4 1-phenylspiro<4.5>deca-6,9-diene-2,8-dione 
• 20238-83-9 dihydro-p-coumaryl aldehyde 

Relevant articles and documents

Divergent reactivity of phenol- and anisole-tethered donor-acceptor α-diazoketones

The first study of the divergent reactivity of phenol/anisole-tethered donor-acceptor α-diazoketones is described. Four distinct product classes were shown to be accessible from closely related α-diazoketone precursors, with the reaction outcome dependent

Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14)

The osteogenic growth peptide (OGP) is a key factor in the mechanism of the systemic osteogenic response to local bone marrow injury. When administered in vivo, OGP stimulates osteogenesis and hematopoiesis. The C-terminal pentapeptide OGP(10-14) is the minimal amino acid sequence that retains the full OGP-like activity. Apparently, it is also the physiologic active form of OGP. Residues Tyr10, Phe12, Gly13, and Gly14 of OGP are essential for the OGP(10-14) activity. The present study explored the functional role of the peptide bonds, carboxyl and amino terminal groups, and conformational freedom in OGP(10-14). Transformations replacing the peptide bonds with surrogates such as ψ(CH2NH), ψ(CONMe), and ψ(CH2CH2) demonstrated that amide bonds do not contribute significantly to OGP(10-14) bioactivity. End-to-end cyclization yielded the fully bioactive cyclic pentapeptide c(Tyr-Gly-Phe-Gly-Gly). The retroinverso analogue c(Gly-Gly-phe-Gly-tyr), a cyclostereoisomer of c(Tyr-Gly-Phe-Gly-Gly), is at least as potent as the parent cyclic pentapeptide. The unique structure-activity relations revealed in this study suggest that the spatial presentation of the Tyr and Phe side chains has a major role in the productive interaction of OGP(10-14) and its truncated and conformationally constrained analogues with their cognate cellular target.